The team of the Department of General Pediatrics and Infectious Diseases of the Necker-Enfants Malades AP-HP Hospital, the Institut Pasteur, Inserm and the University of Paris, conducted a prospective observational study between April 27 and May 15, 2020 to describe the characteristics of children and adolescents hospitalized in a context of Kawasaki disease-like syndrome in a COVID-19 epidemic context, with a systemic hyper-inflammatory expression. The results of this study were published on June 3, 2020 in the journal BMJ.
This work included all children and adolescents hospitalized during the study period with signs of Kawasaki disease. Clinical and biological data, imaging and cardiac ultrasound data, treatments and clinical course were collected. A nasopharyngeal sample for SARS-CoV-2 by RT-PCR and a sample for IgG antibodies against the virus were systematically performed for all patients included.
During the study period, 21 patients were admitted to the general pediatrics and infectious diseases department with signs of Kawasaki disease. Their median age was 7.9 years (range, 3.7-16.6 years), and 12 patients (57%) had a parent or grandparent born in a sub-Saharan African country. Twelve patients (57%) developed shock syndrome related to Kawasaki disease and 16 patients (76%) developed myocarditis. Seventeen patients (81%) required intensive care or pediatric resuscitation. All of these children had noisy digestive symptoms at the onset of the disease and all had high inflammatory markers. Nineteen patients (90%) had markers of recent SARS-CoV-2 infection (RT-PCR positive for 8/21, and presence of IgG antibodies for 19/21 patients). All patients received intravenous immunoglobulins and ten (48%) also received corticosteroids. The clinical course was favorable in all cases. Coronary dilations were detected in five (24%) patients during hospitalization.
A research team from Inserm, Lille University, Lille University Hospital, CNRS, and the Institut Pasteur of Lille, as part of the Lille Immunity and Infection Center, is developing a new vaccine against whooping cough. En utilisant la bactérie entière mais génétiquement modifiée ...
At a time when the Sars-CoV-2 epidemic is continuing to spread, France’s Alliance for Life Sciences and Health (Aviesan) is mobilizing to accelerate research into the virus and COVID-19 disease through REACTing – a consortium coordinated by Inserm. The Scientific Advisory Board ...
Julie Toubiana,1,2 Clément Poirault,1 Alice Corsia,3 Fanny Bajolle,4 Jacques Fourgeaud,5 François Angoulvant,6 Agathe Debray,1 Romain Basmaci,7 Elodie Salvador,3 Sandra Biscardi,8 Pierre Frange,9 Martin Chalumeau,1,10 Jean-Laurent Casanova,11,12 Jérémie F Cohen,1,10 Slimane Allali1
Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study